Benchmark Reiterates Speculative Buy on OncoCyte, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson reiterates a Speculative Buy rating on OncoCyte (NASDAQ:OCX) and maintains a $5 price target.
April 15, 2024 | 3:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson reiterates a Speculative Buy rating on OncoCyte and maintains a $5 price target.
The reiteration of a Speculative Buy rating and maintenance of a $5 price target by a Benchmark analyst could signal confidence in OncoCyte's future performance, potentially influencing investor sentiment positively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100